// App-Quantinova.ai

e13523 : Incidence of mutated DNA damage response pathway and clinically actionable alterations in Chinese patients with unknown primary tumor revealed by comprehensive genomic profiling.

Researchers

Presenter

  • Shibao Wang

Principal Investigators

  • Ruoying Yu

  • Qiuxiang Ou

  • Xue Wu

  • Hua Bao

  • Yang Shao

  • Suju Wei

Medical Centers

  • Department of Medical oncology, China-Japan Union Hospital, Changchun, China

  • Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada

  • Geneseeq Technology Inc., Nanjing, China

  • Department of Radiation Oncology, Fourth Hospital, Hebei Medical University, Shijiazhuang, China

Locations

  • China

  • Canada

Companies

  • Geneseeq Technology

  • Nanjing Geneseeq Tec

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved